|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-4-2
|
|
pubmed:abstractText |
A novel series of quinolinyl-methylene-thiazolinones has been identified as potent and selective cyclin-dependent kinase 1 (CDK1) inhibitors. Their synthesis and structure activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK1 activity in vitro, and block cell cycle progression in human tumor cell lines, suggesting a potential use as antitumor agents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:ChenLiL,
pubmed-author:ChenShaoqingS,
pubmed-author:ChenYingsiY,
pubmed-author:FinkS ISI,
pubmed-author:JacksonNicoleN,
pubmed-author:KonzelmannFredF,
pubmed-author:LeNam TNT,
pubmed-author:LiuJin-JunJJ,
pubmed-author:LouJian PingJP,
pubmed-author:MichoudChristopheC,
pubmed-author:PortlandLouisL,
pubmed-author:QingXiangX,
pubmed-author:RégaPP,
pubmed-author:SidduriAchyutharaoA,
pubmed-author:TovarChristianC,
pubmed-author:VassilevLyubomir TLT,
pubmed-author:ZhaoChunlinC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2134-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.
|
|
pubmed:affiliation |
Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. shaoqing.chen@roche.com
|
|
pubmed:publicationType |
Journal Article
|
